Anton Hagenbeek, MD, PhD of the University of Amsterdam, Netherlands discusses the next steps for Hodgkin lymphoma following the Transplant BRaVE trial (NCT02280993) at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA. According to Prof. Hagenbeek, the next step is to combine the most effective treatments available, i.e. the antibody drug-conjugate brentuximab vedotin plus immune checkpoint inhibitors such as nivolumab and pembrolizumab. To date, no one knows if these types of drugs should be given simultaneously or sequentially; clinical trials are required to answer this question. Prof. Hagebeek explains that we can expect good results with minimal toxicity. If it is possible to induce remissions in a high fraction of patients with acceptable and low toxicity, that would be a major step forward for Hodgkin lymphoma but also diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.